{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:58:35Z","timestamp":1791197915770,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12185-026-04232-z","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T02:51:16Z","timestamp":1782010276000},"page":"559-567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy of prophylactic tranexamic acid in patients with hematologic malignancy: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1120-1230","authenticated-orcid":false,"given":"Teiko","family":"Kawahigashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoharu","family":"Shibusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,21]]},"reference":[{"key":"4232_CR1","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1002\/cncr.22602","volume":"109","author":"H Kantarjian","year":"2007","unstructured":"Kantarjian H, Giles F, List A, Lyons R, Sekeres MA, Pierce S, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007;109:1705\u201314. https:\/\/doi.org\/10.1002\/cncr.22602.","journal-title":"Cancer"},{"key":"4232_CR2","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/ejh.13595","volume":"106","author":"JL Shaw","year":"2021","unstructured":"Shaw JL, Nielson CM, Park JK, Marongiu A, Soff GA. The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies. Eur J Haematol. 2021;106:662\u201372. https:\/\/doi.org\/10.1111\/ejh.13595.","journal-title":"Eur J Haematol"},{"key":"4232_CR3","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1182\/bloodadvances.2022008644","volume":"7","author":"C Hsu","year":"2023","unstructured":"Hsu C, Patell R, Zwicker JI. The prevalence of thrombocytopenia in patients with acute cancer-associated thrombosis. Blood Adv. 2023;7:4721\u20137. https:\/\/doi.org\/10.1182\/bloodadvances.2022008644.","journal-title":"Blood Adv"},{"key":"4232_CR4","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1056\/NEJMoa0904084","volume":"362","author":"SJ Slichter","year":"2010","unstructured":"Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362:600\u201313. https:\/\/doi.org\/10.1056\/NEJMoa0904084.","journal-title":"N Engl J Med"},{"key":"4232_CR5","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1212772","volume":"368","author":"SJ Stanworth","year":"2013","unstructured":"Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013;368:1771\u201380. https:\/\/doi.org\/10.1056\/NEJMoa1212772.","journal-title":"N Engl J Med"},{"key":"4232_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.21037\/aob-20-90","volume":"6","author":"T Sato","year":"2021","unstructured":"Sato T, Tsuno NH, Goto N, Hagino T, Tasaki T. Incidence and severity of adverse effects related to platelet transfusion: a narrative review of the literature and the recent hemovigilance data of Japan. Ann Blood. 2021;6:24\u201324. https:\/\/doi.org\/10.21037\/aob-20-90.","journal-title":"Ann Blood"},{"key":"4232_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2014.11.004","author":"S Nahirniak","year":"2015","unstructured":"Nahirniak S, Slichter SJ, Tanael S, Rebulla P, Pavenski K, Vassallo R, et al. Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia. Transfus Med Rev. 2015. https:\/\/doi.org\/10.1016\/j.tmrv.2014.11.004.","journal-title":"Transfus Med Rev"},{"key":"4232_CR8","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.jaci.2014.03.030","volume":"133","author":"WJ Savage","year":"2014","unstructured":"Savage WJ, Hamilton RG, Tobian AAR, Milne GL, Kaufman RM, Savage JH, et al. Defining risk factors and presentations of allergic reactions to platelet transfusion. J Allergy Clin Immunol. 2014;133:1772-1775.e9. https:\/\/doi.org\/10.1016\/j.jaci.2014.03.030.","journal-title":"J Allergy Clin Immunol"},{"key":"4232_CR9","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1016\/j.arth.2018.08.002","volume":"33","author":"YA Fillingham","year":"2018","unstructured":"Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, Bini SA, Clarke HD, et al. Tranexamic acid use in total joint arthroplasty: the clinical practice guidelines endorsed by the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and Knee Society. J Arthroplasty. 2018;33:3065\u20139. https:\/\/doi.org\/10.1016\/j.arth.2018.08.002.","journal-title":"J Arthroplasty"},{"key":"4232_CR10","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1161\/CIRCULATIONAHA.106.671222","volume":"115","author":"JR Brown","year":"2007","unstructured":"Brown JR, Birkmeyer NJO, O\u2019Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation. 2007;115:2801\u201313. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.671222.","journal-title":"Circulation"},{"key":"4232_CR11","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1056\/NEJMoa2201171","volume":"386","author":"PJ Devereaux","year":"2022","unstructured":"Devereaux PJ, Marcucci M, Painter TW, Conen D, Lomivorotov V, Sessler DI, et al. Tranexamic acid in patients undergoing noncardiac surgery. N Engl J Med. 2022;386:1986\u201397. https:\/\/doi.org\/10.1056\/NEJMoa2201171.","journal-title":"N Engl J Med"},{"key":"4232_CR12","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/S0140-6736(17)30638-4","volume":"389","author":"WOMAN Trial Collaborators","year":"2017","unstructured":"WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389:2105\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(17)30638-4.","journal-title":"Lancet"},{"key":"4232_CR13","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/S0140-6736(19)32233-0","volume":"394","author":"The CRASH 2 Collaborators","year":"2019","unstructured":"The CRASH 2 Collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. The Lancet. 2019;394:1713\u201323. https:\/\/doi.org\/10.1016\/S0140-6736(19)32233-0.","journal-title":"The Lancet"},{"key":"4232_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta17100","volume":"17","author":"I Roberts","year":"2013","unstructured":"Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013;17:1\u201379. https:\/\/doi.org\/10.3310\/hta17100.","journal-title":"Health Technol Assess"},{"key":"4232_CR15","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(20)30848-5","volume":"395","author":"I Roberts","year":"2020","unstructured":"Roberts I, Shakur-Still H, Afolabi A, Akere A, Arribas M, Brenner A, et al. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet. 2020;395:1927\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(20)30848-5.","journal-title":"Lancet"},{"key":"4232_CR16","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/S1474-4422(20)30369-0","volume":"19","author":"A Meretoja","year":"2020","unstructured":"Meretoja A, Yassi N, Wu TY, Churilov L, Sibolt G, Jeng J-S, et al. Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2020;19:980\u20137. https:\/\/doi.org\/10.1016\/S1474-4422(20)30369-0.","journal-title":"Lancet Neurol"},{"key":"4232_CR17","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1016\/S0140-6736(18)31033-X","volume":"391","author":"N Sprigg","year":"2018","unstructured":"Sprigg N, Flaherty K, Appleton JP, Al-Shahi Salman R, Bereczki D, Beridze M, et al. Tranexamic acid for hyperacute primary intracerebral haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet. 2018;391:2107\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(18)31033-X.","journal-title":"Lancet"},{"key":"4232_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2025.09.009","author":"T Alsuliman","year":"2025","unstructured":"Alsuliman T, Chalayer E, Stocker N, Garidi R, Crichi B, Marjanovic Z, et al. Tranexamic acid to prevent bleeding in patients with hematologic malignancies and hypoproliferative thrombocytopenia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. J Thromb Haemost. 2025. https:\/\/doi.org\/10.1016\/j.jtha.2025.09.009.","journal-title":"J Thromb Haemost"},{"key":"4232_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. Statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"4232_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/ebmed-2017-110713","volume":"22","author":"MH Murad","year":"2017","unstructured":"Murad MH, Wang Z. Guidelines for reporting meta-epidemiological methodology research. Evid Based Med. 2017;22:139\u201342. https:\/\/doi.org\/10.1136\/ebmed-2017-110713.","journal-title":"Evid Based Med"},{"key":"4232_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.2017.76.1734","volume":"36","author":"CA Schiffer","year":"2018","unstructured":"Schiffer CA, Bohlke K, Delaney M, Hume H, Magdalinski AJ, McCullough JJ, et al. Platelet transfusion for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018;36:283\u201399. https:\/\/doi.org\/10.1200\/JCO.2017.76.1734.","journal-title":"J Clin Oncol"},{"key":"4232_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/bjh.14423","volume":"176","author":"LJ Estcourt","year":"2017","unstructured":"Estcourt LJ, Birchall J, Allard S, Bassey SJ, Hersey P, Kerr JP, et al. Guidelines for the use of platelet transfusions. Br J Haematol. 2017;176:365\u201394. https:\/\/doi.org\/10.1111\/bjh.14423.","journal-title":"Br J Haematol"},{"key":"4232_CR23","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"4232_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383\u201394. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.026.","journal-title":"J Clin Epidemiol"},{"key":"4232_CR25","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2352-3026(24)00317-X","volume":"12","author":"LJ Estcourt","year":"2025","unstructured":"Estcourt LJ, McQuilten ZK, Bardy P, Cole-Sinclair M, Collins GP, Crispin PJ, et al. Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial. Lancet Haematol. 2025;12:e14\u201322. https:\/\/doi.org\/10.1016\/S2352-3026(24)00317-X.","journal-title":"Lancet Haematol"},{"key":"4232_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3663-2","author":"LJ Estcourt","year":"2019","unstructured":"Estcourt LJ, McQuilten Z, Powter G, Dyer C, Curnow E, Wood EM, et al. The TREATT trial (trial to evaluate tranexamic acid therapy in thrombocytopenia): Safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: Study protocol for a double-blind randomised controlled trial. Trials. 2019. https:\/\/doi.org\/10.1186\/s13063-019-3663-2.","journal-title":"Trials"},{"key":"4232_CR27","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1182\/blood.2022016308","volume":"140","author":"TB Gernsheimer","year":"2022","unstructured":"Gernsheimer TB, Brown SP, Triulzi DJ, Key NS, El Kassar N, Herren H, et al. Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial. Blood. 2022;140:1254\u201362. https:\/\/doi.org\/10.1182\/blood.2022016308.","journal-title":"Blood"},{"key":"4232_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102358","author":"JN Poston","year":"2024","unstructured":"Poston JN, Brown SP, Ilich A, Ginsburg AS, Herren H, El Kassar N, et al. Fewer severe infections with tranexamic acid in patients with hematologic malignancies. Res Pract Thromb Haemost. 2024. https:\/\/doi.org\/10.1016\/j.rpth.2024.102358.","journal-title":"Res Pract Thromb Haemost"},{"key":"4232_CR29","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1111\/trf.18028","volume":"64","author":"JN Poston","year":"2024","unstructured":"Poston JN, Brown SP, Ginsburg AS, Ilich A, Herren H, El Kassar N, et al. Analysis of bleeding outcomes in patients with hypoproliferative thrombocytopenia in the A-TREAT clinical trial. Transfusion (Paris). 2024;64:2055\u201362. https:\/\/doi.org\/10.1111\/trf.18028.","journal-title":"Transfusion (Paris)"},{"key":"4232_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3109\/10428199509059668","volume":"19","author":"O Shpilberg","year":"1995","unstructured":"Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, et al. A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. Leuk Lymphoma. 1995;19:141\u20134. https:\/\/doi.org\/10.3109\/10428199509059668.","journal-title":"Leuk Lymphoma"},{"key":"4232_CR31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1046\/j.1537-2995.1991.31491213301.x","volume":"31","author":"W Fricke","year":"1991","unstructured":"Fricke W, Alling D, Kimball J, Griffith P, Klein H. Lack of efficacy of tranexamic acid in thrombocytopenic bleeding. Transfusion (Paris). 1991;31:345\u20138. https:\/\/doi.org\/10.1046\/j.1537-2995.1991.31491213301.x.","journal-title":"Transfusion (Paris)"},{"key":"4232_CR32","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/s0140-6736(89)90181-5","volume":"2","author":"G Avvisati","year":"1989","unstructured":"Avvisati G, ten Cate JW, B\u00fcller HR, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet. 1989;2:122\u20134. https:\/\/doi.org\/10.1016\/s0140-6736(89)90181-5.","journal-title":"Lancet"},{"key":"4232_CR33","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1055\/s-0037-1615947","volume":"85","author":"M Hoffman","year":"2001","unstructured":"Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost. 2001;85:958\u201365.","journal-title":"Thromb Haemost"},{"key":"4232_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hoc.2006.11.004","volume":"21","author":"M Hoffman","year":"2007","unstructured":"Hoffman M, Monroe DM. Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am. 2007;21:1\u201311. https:\/\/doi.org\/10.1016\/j.hoc.2006.11.004.","journal-title":"Hematol Oncol Clin North Am"},{"key":"4232_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa2215457","volume":"389","author":"Prehospital Tranexamic Acid for Severe Trauma","year":"2023","unstructured":"Prehospital Tranexamic Acid for Severe Trauma. N Engl J Med. 2023;389:127\u201336. https:\/\/doi.org\/10.1056\/NEJMoa2215457.","journal-title":"N Engl J Med"},{"key":"4232_CR36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0140-6736(20)32518-6","volume":"397","author":"R Post","year":"2021","unstructured":"Post R, Germans MR, Tjerkstra MA, Vergouwen MDI, Jellema K, Koot RW, et al. Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial. Lancet. 2021;397:112\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(20)32518-6.","journal-title":"Lancet"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04232-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04232-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04232-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:59:15Z","timestamp":1791194355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04232-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4232"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04232-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,21]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No institutional review board approval was required because this study uses de-identified data without direct human subject involvement.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was prospectively registered on the Open Science Framework (OSF) on April 20, 2025 (registration available at:\n                      \n                      ).","order":3,"name":"Ethics","label":"Clinical trial registration","group":{"name":"EthicsHeading","label":"Declarations"}}]}}